for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Altimmune Inc

ALT.OQ

Latest Trade

2.03USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.70

 - 

5.93

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.03
Open
--
Volume
--
3M AVG Volume
3.32
Today's High
--
Today's Low
--
52 Week High
5.93
52 Week Low
1.70
Shares Out (MIL)
15.34
Market Cap (MIL)
31.44
Forward P/E
-2.30
Dividend (Yield %)
--

Next Event

Altimmune Inc at H C Wainwright NASH Investor Conference

Latest Developments

More

Altimmune Reports Q2 Loss Per Share Of $0.26

Altimmune Announces Closing Of Acquisition Of Spitfire Pharma Inc

Altimmune To Acquire Spitfire Pharma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Altimmune Inc

Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor immunostimulant product candidate that has the potential to safely elicit or improve immune responses in a variety of cancer indications. NasoVAX, its influenza vaccine candidate that stimulate multiple arms of the immune system and offers the potential to stop the infection and the spread of flu, while being easier to administer through an intranasal spray. NasoShield is an intranasal anthrax vaccine candidate that is designed to provide more rapid and stable protection than the only approved anthrax vaccine.

Industry

Biotechnology & Drugs

Contact Info

910 Clopper Rd Ste 201S

+1.240.6541450

https://altimmune.com/

Executive Leadership

Mitchel B. Sayare

Chairman of the Board

Vipin K. Garg

President, Chief Executive Officer, Director

William Michael Brown

Chief Financial Officer, Principal Accounting Officer

M. Scot Roberts

Chief Scientific Officer

David J. Drutz

Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-120.300

2018

-14.130

2019(E)

-0.890
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.21
Price To Book (MRQ)
0.49
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.61
LT Debt To Equity (MRQ)
2.88
Return on Investment (TTM)
-62.48
Return on Equity (TTM)
-56.70

Latest News

Latest News

BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine

* ALTIMMUNE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE AND PROVIDES AN UPDATE ON ITS PHASE 1B STUDY OF HEPTCELL TARGETED IMMUNOTHERAPY IN CHRONIC HEPATITIS B INFECTION

BRIEF-Altimmune Announces Pre-Clinical Data From Its Sparvax-L Anthrax Vaccine Program

* ALTIMMUNE ANNOUNCES PRE-CLINICAL DATA FROM ITS SPARVAX-L ANTHRAX VACCINE PROGRAM

BRIEF-Hudson Bay Capital Management Reports A 9.99 Percent Passive Stake In Altimmune

* HUDSON BAY CAPITAL MANAGEMENT LP REPORTS A 9.99 PERCENT PASSIVE STAKE IN ALTIMMUNE, INC AS OF DECEMBER 31, 2017 - SEC FILING Source text for Eikon: [http://bit.ly/2nwUAiB] Further company coverage:

BRIEF-Altimmune Announces Allowance On Patent Covering Use Of Nasoshield In U.S.

* ALTIMMUNE ANNOUNCES NOTICE OF ALLOWANCE ON PATENT COVERING USE OF NASOSHIELD IN THE U.S. Source text for Eikon: Further company coverage:

BRIEF-Altimmune Elects Mitchel Sayare As Chairman Of Its Board

* ALTIMMUNE ELECTS MITCHEL SAYARE, PH.D. AS CHAIRMAN OF ITS BOARD OF DIRECTORS

BRIEF-Altimmune reports Q3 loss per share $2.05

* Altimmune announces third quarter 2017 financial results and provides corporate update

BRIEF-Altimmune to provide corporate update at Rodman & Renshaw global investment conference

* Altimmune to provide corporate update at the Rodman & Renshaw global investment conference Source text for Eikon: Further company coverage:

BRIEF-Altimmune submits investigational new drug application for Nasovax for phase 2 trial preparation

* Altimmune submits investigational new drug application for Nasovax in preparation for Phase 2 trial

BRIEF-Altimmune announces $14.7 million Series B preferred stock offering

* Altimmune announces $14.7 million Series B preferred stock offering

BRIEF-Altimmune posts Q2 loss of $0.26 per share

* Altimmune announces second quarter 2017 financial results and provides corporate update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up